
Annual report 2025
added 03-30-2026
Annexon Net Debt 2011-2026 | ANNX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Annexon
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -136 M | -20.5 M | -194 M | -107 M | -40.3 M | -269 M | -43.9 M | -44.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.5 M | -269 M | -107 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ADC Therapeutics SA
ADCT
|
-459 M | $ 3.78 | - | $ 105 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.35 | -2.17 % | $ 347 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.5 | -21.7 % | $ 236 B | ||
|
Aldeyra Therapeutics
ALDX
|
-129 M | $ 1.58 | -4.82 % | $ 94.9 M | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 8.36 | 4.89 % | $ 82.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 330.71 | 3.72 % | $ 43.3 B | ||
|
Altimmune
ALT
|
-9.22 M | $ 3.47 | 3.89 % | $ 306 M | ||
|
ALX Oncology Holdings
ALXO
|
-10.9 M | $ 1.98 | 0.25 % | $ 106 M | ||
|
Amgen
AMGN
|
41 B | $ 346.45 | -0.43 % | $ 186 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Amneal Pharmaceuticals
AMRX
|
2.29 B | $ 12.37 | -0.92 % | $ 3.88 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 15.0 | 1.32 % | $ 220 M | ||
|
ANI Pharmaceuticals
ANIP
|
166 M | $ 76.34 | 2.87 % | $ 1.47 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.92 | -1.11 % | $ 5.02 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Aprea Therapeutics
APRE
|
-130 M | $ 0.73 | 2.63 % | $ 4.77 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.15 | 0.48 % | $ 444 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 8.43 | 4.98 % | $ 231 M | ||
|
Ardelyx
ARDX
|
136 M | $ 6.08 | 2.27 % | $ 1.47 B | ||
|
argenx SE
ARGX
|
-89.9 M | $ 752.05 | 0.75 % | $ 25 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
-141 M | $ 11.11 | 2.4 % | $ 788 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 61.57 | 0.88 % | $ 8.24 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Assembly Biosciences
ASMB
|
-55.8 M | $ 30.01 | 3.43 % | $ 336 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Actinium Pharmaceuticals
ATNM
|
-46.3 M | $ 1.14 | 16.28 % | $ 35.6 M | ||
|
Atossa Therapeutics
ATOS
|
-39.6 M | $ 5.21 | -2.89 % | $ 44.9 M | ||
|
Atara Biotherapeutics
ATRA
|
1.89 M | $ 5.03 | 0.7 % | $ 63.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
-26.8 M | $ 16.04 | 2.75 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.42 | 0.35 % | $ 378 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M |